Alexion Pharmaceuticals Given New $185.00 Price Target at UBS AG (ALXN)
Research analysts at UBS AG raised their price objective on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $150.00 to $185.00 in a report released on Friday, AmericanBankingNews.com reports. UBS AG’s price target points to a potential upside of 16.55% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group raised their price target on shares of Alexion Pharmaceuticals from $106.00 to $145.00 in a research note to investors on Friday. They now have a “hold” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Alexion Pharmaceuticals from $125.00 to $200.00 in a research note to investors on Friday. Finally, analysts at Canaccord Genuity raised their price target on shares of Alexion Pharmaceuticals from $161.00 to $200.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $151.22.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 158.73 on Friday. Alexion Pharmaceuticals has a 52 week low of $81.82 and a 52 week high of $169.98. The stock has a 50-day moving average of $134.5 and a 200-day moving average of $119.3. The company has a market cap of $31.123 billion and a price-to-earnings ratio of 91.63.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. Analysts expect that Alexion Pharmaceuticals will post $3.60 EPS for the current fiscal year.
In other Alexion Pharmaceuticals news, EVP Stephen P. Squinto unloaded 1,118 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $133.31, for a total value of $149,040.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.